Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Zoster Vaccine in SLE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. SLE patients who fulfill ≥4 of the 1997 ACR (17) or the 2012 SLICC/ACR criteria for SLE (18)~2. Age ≥18 years~3. Clinically inactive disease with SELENA-SLEDAI score \<6 (see below) and receiving stable dose of immunosuppressive agents for ≥6 months~4. History of varicella (chickenpox) or herpes zoster infection in the past~5. Willing to comply with all study procedures~Exclusion Criteria:~1. Active infection, including upper respiratory tract infection~2. Active untreated tuberculosis~3. Human immunodeficiency virus (HIV) infection~4. Lymphocyte count \<500/mm2~5. Reduced serum IgG, IgA or IgM level (below normal range)~6. Serum creatinine \>200umol/L~7. History of hematological malignancies (eg. lymphoma, leukaemia) and other solid tumors~8. Patients receiving doses of immunosuppressive agents exceeding the following:~   * Prednisolone (\>15mg) or equivalent~  * Azathioprine (\>100mg/day)~  * Mycophenolate mofetil (\>1000mg/day)~  * Cyclosporin A (\>100mg/day)~  * Tacrolimus (\>3mg/day)~  * Methotrextate (\>15mg/week)~  * Cyclophosphamide (any dose)~  * Biological agents eg. rituximab, belimumab (any dose)~9. Patients who are pregnant or plan to become pregnancy within one year of study entry~10. Patients who cannot give a written consent (mentally incapable or illiterate)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SLE (vaccine) (Type: ACTIVE_COMPARATOR): Zostavax SC injection (0.65ml)
- SLE (placebo) (Type: PLACEBO_COMPARATOR): Placebo SC injection (normal saline 0.65ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).